Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation.

Journal: Blood advances
Published Date:

Abstract

Acute graft-versus-host disease (aGVHD) is 1 of the critical complications that often occurs following allogeneic hematopoietic stem cell transplantation (HSCT). Thus far, various types of prediction scores have been created using statistical calculations. The primary objective of this study was to establish and validate the machine learning-dependent index for predicting aGVHD. This was a retrospective cohort study that involved analyzing databases of adult HSCT patients in Japan. The alternating decision tree (ADTree) machine learning algorithm was applied to develop models using the training cohort (70%). The ADTree algorithm was confirmed using the hazard model on data from the validation cohort (30%). Data from 26 695 HSCT patients transplanted from allogeneic donors between 1992 and 2016 were included in this study. The cumulative incidence of aGVHD was 42.8%. Of >40 variables considered, 15 were adapted into a model for aGVHD prediction. The model was tested in the validation cohort, and the incidence of aGVHD was clearly stratified according to the categorized ADTree scores; the cumulative incidence of aGVHD was 29.0% for low risk and 58.7% for high risk (hazard ratio, 2.57). Predicting scores for aGVHD also demonstrated the link between the risk of development aGVHD and overall survival after HSCT. The machine learning algorithms produced clinically reasonable and robust risk stratification scores. The relatively high reproducibility and low impacts from the interactions among the variables indicate that the ADTree algorithm, along with the other data-mining approaches, may provide tools for establishing risk score.

Authors

  • Yasuyuki Arai
    Department of Transfusion Medicine and Cell Therapy and.
  • Tadakazu Kondo
    Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kyoko Fuse
    Faculty of Medicine, Department of Hematology, Endocrinology and Metabolism, Niigata University, Niigata, Japan.
  • Yasuhiko Shibasaki
    Department of Hematopoietic Cell Transplantation, Niigata University Medical and Dental Hospital, Niigata, Japan.
  • Masayoshi Masuko
    Department of Hematopoietic Cell Transplantation, Niigata University Medical and Dental Hospital, Niigata, Japan.
  • Junichi Sugita
    Department of Hematology, Hokkaido University Hospital, Hokkaido, Japan.
  • Takanori Teshima
    Department of Hematology, Hokkaido University Hospital, Hokkaido, Japan.
  • Naoyuki Uchida
    Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Tokyo, Japan.
  • Takahiro Fukuda
    Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Kazuhiko Kakihana
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Yukiyasu Ozawa
    Department of Hematology, Japanese Red Cross Nagoya First Hospital, Aichi, Japan.
  • Tetsuya Eto
    Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
  • Masatsugu Tanaka
    Department of Hematology, Kanagawa Cancer Center, Kanagawa, Japan.
  • Kazuhiro Ikegame
    Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
  • Takehiko Mori
    Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Koji Iwato
    Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
  • Tatsuo Ichinohe
    Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Yoshinobu Kanda
    Division of Hematology, Jichi Medical University, Saitama, Japan.
  • Yoshiko Atsuta
    Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan; and.